- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDG-PET Shows Promise for Lung Cancer Patient Prognoses
Post-treatment FDG-PET scans show promise for predicting the prognosis of patients with inoperable non-small cell lung cancer, the principal investigator of a major clinical trial reported today at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Miami Beach, Fla.
Post-treatment FDG-PET scans show promise for predicting the prognosis of patients with inoperable non-small cell lung cancer, the principal investigator of a major clinical trial reported today at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Miami Beach, Fla.
The prognosis for patients with stage 2 and 3 inoperable non-small cell lung cancer (NSCLC) is poor, with only about 15 percent of patients surviving at five years post-treatment for the disease. While new treatment strategies are being intensely studied, timely assessment of their efficacy has proven difficult.
“These results are encouraging,” said Mitchell Machtay, MD, principal investigator of the ACRIN 6668/RTOG 0235 trial. “Definitive prognostic information after a patient completes therapy has not been available for making decisions about further treatment options, and these preliminary results suggest that FDG-PET may play an important role in that regard.”
Twenty ACRIN and RTOG participating sites enrolled 251 patients into the phase III trial that gathered pre- and post-treatment FDG-PET (F-18 fluorodeoxyglucose-positron emission tomography) scans. Their treatment included both chemotherapy and radiation therapy. Investigators wondered if the standardized uptake value (SUV) - a quantitative measure of how rapidly tumor cells are using the glucose-based FDG radiotracer - was predictive of a patient’s survival. SUV was obtained on post-treatment FDG-PET scans.
Patients with high levels of FDG uptake after treatment had more aggressive tumors that were more likely to recur, Machtay said.
“The higher the SUV measure in the primary tumor, the greater the recurrence rate and the lower a patient’s corresponding survival outlook,” he added.
“The results announced today suggest that FDG-PET has a role in helping physicians make more informed treatment decisions, such as starting a patient on a new chemotherapy program,” said Barry Siegel, MD, ACRIN co-deputy chair and medical director of the ACR PET Imaging Core Laboratory, “and helping investigators determine whether a treatment regimen is worthy of further study before long-term survival data are available.”
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
